AZD929 (Osimertinib) is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC). The mechanism of action of AZD929 (Osimertinib )is as a Kinase Inhibitor, and Cytochrome P450 3A Inhibitor, and Cytochrome P450 3A4 Inducer, and Cytochrome P450 1A2 Inducer, and Breast Cancer Resistance Protein Inhibitor.
The physical appearance of AZD929 Osimertinib is white to off white solid. AZD929 (Osimertinib) is soluble in Acetonitrile or Dimethyl sulfoxide.
Notice: If the compound involved in patent protection, do not use for commercial purposes, and only for the purpose of analysis and research experiments. If it’s sold to countries which constitute patent infringement, All the risks corresponding are unrelated to our company.